What can aggregate randomized data establish about treatment duration and benefit–risk?
SCOT trial efficacy and neuropathy compared with endpoint-specific denominators, uncertainty, missingness bounds and limits of joint benefit–risk inference.
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
Recent writing
抗PD-1抗体の固定用量は、極端な体重の患者でも曝露を保てるか
公表PopPKモデルと一般成人の体重分布で、pembrolizumab・nivolumabの固定用量と体重換算を比べた。固定用量は重い側で、体重換算は軽い側の初回投与でトラフが試験の範囲を下回りやすい。曝露の比較であり、用量は推奨しない。
RAS inhibitor dosing: from public PK/PD data to target-coverage scenarios
Public blood–tumor–DUSP6 reconstruction and hypothetical QD/BID comparisons with target turnover, variability and exposure costs.